Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review

References

• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin-therapy – European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. A report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68:92–125.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–383.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–1036.
   PubMed Web of Science ®Google Scholar
• Bergeron N, Phan BAP, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition. A new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132:1648–1666.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272.
   PubMed Web of Science ®Google Scholar
• Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833–2842.
   PubMed Web of Science ®Google Scholar
• Hedrick JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Invest Drugs. 2009;10:938–946.
   PubMed Web of Science ®Google Scholar
• Elbitar S, Khoury PE, Ghaleb Y, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011–2015). Expert Opin Ther Pat. 2016;12:1–16.
   Google Scholar
• Farnier M. An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Rev Cardiovasc Ther. 2015;13:1307–1323.
   PubMed Web of Science ®Google Scholar
• Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Rev Cardiovasc Ther. 2015;13:477–488.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352–362.
   PubMed Web of Science ®Google Scholar
• Packard CJ. Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism. Circulation. 2017;135:363–365.
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC, Dent R, et al. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation. 2017;135:338–351.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015;4:e002224.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc Drugs Ther. 2016;30:473–483.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11:195–203.
   PubMed Web of Science ®Google Scholar
• Defesche JC, Stefanutti C, Langslet G, et al. Efficacy of alirocumab in 1911 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 ;11:1338.e7–1346.e7.
   Google Scholar
• Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet. 2015;8:823–831.
   PubMed Web of Science ®Google Scholar
• Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.
   PubMed Web of Science ®Google Scholar
• Dufour R, Bergeron J, Gaudet D, et al. Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: results from three years of treatment. Intern J Cardiol. 2017;228:754–760.
   PubMed Web of Science ®Google Scholar
• Farnier M, Hovingh GK, Langslet G, et al. Durability of alirocumab effects: data from an open-label extension to the ODYSSEY program for patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11:840.
   Google Scholar
• Bernelot Moens SJ, Neele AE, Kroon J, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolemia. Eur Heart J. 2017;38:1584–1593.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588–3595.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Farnier M, Robinson JG, et al. Efficacy and safety of alirocumab: pooled analysis of 1048 individuals with diabetes mellitus from five placebo-controlled phase 3 studies of at least 52 weeks duration. Circulation. 2015;132:A17070.
   Google Scholar
• Leiter LA, Zamorano JL, Bujas-Bobanovic M, et al. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017;19:989–996.
   PubMed Web of Science ®Google Scholar
• Cariou B, Leiter LA, Müller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab. 2017 Mar 24;43:453–459.
   PubMedGoogle Scholar
• Müller-Wieland D, Leiter LA, Cariou B, et al. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017;16:70.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Cariou B, Müller-Wieland D, et al. Efficacy and safety alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781–1792.
   PubMed Web of Science ®Google Scholar
• Henry RR Alirocumab vs usual care in diabetes with mixed dyslipidemia — ODYSSEY DM-DYSLIPIDEMIA study. Presented at: American Diabetes Association 77th Scientific Sessions; 2017 Jun 9–13; San Diego, CA. Presentation 1-AC-SY12.
   Google Scholar
• Farnier M, Gaudet D, Valcheva V, et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY phase 3 clinical program trials. Int J Cardiol. 2016;223:750–757.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Lee LV, Louie MJ, et al. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY phase 3 clinical trials. Sci Rep. 2017 Apr 4;7:45788.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Kereiakes DJ, Cannon CP, et al. Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemias. Coron Artery Dis. 2017;28:190–197.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Müller-Wieland D, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabet Med. 2017 Aug 11. doi: 10.1111/dme.13450. [Epub ahead of print].
   PubMedGoogle Scholar
• Bays HE, Leiter LA, Colhoun HM, et al. Alirocumab treatment and achievement of non-high-density lipoprotein cholesterol and apolipoprotein B goals in patients with hypercholesterolemia: pooled results from 10 phase 3 ODYSSEY trials. J Am Heart Assoc. 2017;6:e005639.
   PubMedGoogle Scholar
• El Shahawy M, Cannon CP, Blom DJ, et al. Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). Am J Cardiol. 2017;120:931–939.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Watts GF, Robinson JG, et al. Effect of alirocumab on lipoprotein(a) over ≥ 1.5 years (from the phase 3 ODYSSEY program). Am J Cardiol. 2017;119:40–46.
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Zhang W, et al. The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition induced reduction in Lp(a) with alirocumab. J Lipid Res. 2017;58:2008–2016.
   PubMed Web of Science ®Google Scholar
• Lambert G, Thedrez A, Croyal M, et al. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Clin Sci (Lond). 2017;131:261–268.
   PubMed Web of Science ®Google Scholar
• Tavori H, Devon C, Minnier J, et al. PCSK9 association with lipoprotein (a). Circ Res. 2016;119:29–35.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344–2353.
   PubMed Web of Science ®Google Scholar
• Rey J, Poitiers F, Paehler T, et al. Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid-lowering strategies. J Am Heart Assoc. 2016;5:e003323.
   PubMed Web of Science ®Google Scholar
• Roth EM, Moriarty PM, Bergeron J, et al.; for the ODYSSEY CHOICE I investigators. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:254–262.
   PubMed Web of Science ®Google Scholar
• Stroes E, Guyton JR, Lepor N, et al.; for the ODYSSEY CHOICE II investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016;5:e003421.
   PubMed Web of Science ®Google Scholar
• Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410–414.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Sasaki J, Ishibashi S, et al. Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan – 2012. J Atheroscler Thromb. 2013;20:603–615.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Kobayashi M, Tasaki H, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins. ODYSSEY JAPAN randomized controlled trial. Circ J. 2016;80:1980–1987.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Kondo A, Kiyosue A, et al. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis. 2017;16:121.
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117:40–47.
   PubMed Web of Science ®Google Scholar
• Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016;118:1805–1811.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab. J Am Coll Cardiol. 2017;69:471–482.
   PubMed Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5:97–105.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes. A meta-analysis. JAMA. 2016;316:1383–1391.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. Eur Heart J. 2016;37:2981–2989.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomized controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–950.
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolemia: a network meta-analysis. Eur Heart J. 2016;37:536–545.
   PubMed Web of Science ®Google Scholar
• Khan AR, Bavishi C, Riaz H, et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes. 2017;10:e003153.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–643.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Pedersen TR, Park J-G, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–1971.
   PubMed Web of Science ®Google Scholar
• Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017;376:1589–1590.
   PubMed Web of Science ®Google Scholar
• Ramanathan A, Gusarova V, Stahl N, et al. Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PloS One. 2016;11:e0154498.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–2948.
   PubMed Web of Science ®Google Scholar
• Farnier M, Colhoun HM, Sasiela WJ, et al. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol. 2017;11:986–997.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
   PubMed Web of Science ®Google Scholar
• Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events. A pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016;134:1931–1943.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168:682.e1–689.e1.
   Web of Science ®Google Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2017. doi: 10.1093/eurheartj/ehx450 [Epub ahead of print].
   Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al.; for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al.; for the SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(9):959–966. doi: 10.1001/jamacardio.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069–1078.
   PubMed Web of Science ®Google Scholar
• Arrieta A, Hong JC, Khera R, et al. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers. Insights derived from the FOURIER trial. JAMA Cardiol. 2017 Oct 18. doi: 10.1001/jamacardio.2017.3655. [Epub ahead of print].
   PubMedGoogle Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2017;70:1785–1822.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Chapman MJ, Stock JK, et al. 2017 update of ESC/EAS Task Force on practical clinical guidance for PCSK9 inhibition in patients with ASCVD or in familial hypercholesterolaemia. Eur Heart J. 2017 Oct 16. doi: 10.1093/eurheartj/ehx549. [Epub ahead of print].
   Google Scholar
• Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412–2421.
   PubMed Web of Science ®Google Scholar